Effect of interferon-alpha therapy on hepatitis D virus

Hepatology

Volumn 61, Issue 6, 2015, Pages 2117-2118

  Goyal, Ashish ^a   Murray, John M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE; VIRUS DNA; VIRUS RNA; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; MACROGOL DERIVATIVE;

ANTIVIRAL THERAPY; DELTA AGENT HEPATITIS; HALF LIFE TIME; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; LETTER; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; VIRION; BIOLOGICAL MODEL; BLOOD; DRUG EFFECTS; FEMALE; HUMAN; MALE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; MALE; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; RNA, VIRAL;

EID: 84929605681     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27595     Document Type: Letter

References (6)

1. Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, et al. Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modeling. Hepatology 2014;60:1902-1910.
2. Sypsa VA, Mimidis K, Tassopoulos NC, Chrysagis D, Vassiliadis T, Moulakakis A, et al. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative. Hepatology 2005;42:77-85.
3. + T cells in a population of HIV-infected individuals. J Virol 2011;85:10798-10805.
4. Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 2012;55:685-694.
5. Lewin SR, Ribeiro RM, Avihingsanon A, Bowden S, Matthews G, Marks P, et al. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology 2009;49:1113-1121.
6. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003;112:407-414.